BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate ...

Lighthouse secured a grant of $49.2m from the National Institute on Aging (NIA) to facilitate study of LHP588 for Alzheimer's ...

The FDA has announced it will no longer accept clinical trials that involve sending US patients cells from US to China for ...

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...

As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in ...

This webinar offers essential tools and insights to help organisations confidently navigate the BioSecure Act, ensuring they ...

Reunion Neuroscience will be advancing its psychedelic therapy RE104 to a Phase III trial in post-partum depression (PPD) in ...

Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.

BioAge Labs has dosed the first subject in the Phase I study of BGE-102, under development initially for treating obesity.